# Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

> **NCT00933686** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 113 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** Saizen®
- **DRUG:** Placebo and Saizen®

## Key facts

- **NCT ID:** NCT00933686
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2013-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00933686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00933686, "Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00933686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*